Select research highlights from current AACR journals

September 01, 2004

From the September 1 issue of Cancer Research:

  • Aberrations in the receptor protein dystroglycan may lead to either muscular dystrophy or the development of carcinomas. Whereas several molecular defects in muscle disease have been characterized, little is known about such changes in carcinoma cells. Singh et al. identified multiple post-translational modifications that modulate dystroglycan function in these aberrant cells. Novel defects in carcinoma cells arising in this important cell adhesion molecule are similar to defects recently identified in muscular dystrophies. The research was conducted at the Lawrence Berkley National Laboratories, Berkley, Calif,; the University of Iowa, Iowa City, Iowa; and California Pacific Medical Center Research Institute, San Francisco, Calif.

    Among research findings featured in the September 1 issue of Clinical Cancer Research are:

  • Heat therapy increases the efficacy of tumor treatment with melphalan, an alkylating agent used in cancer therapy for ovarian cancer and certain bone marrow tumors. In rat models for fibrosarcomas, Abdel-Wahab et al. documented that heat treatment with warm water heightened the response of tumors to high doses of melphalan. The effect was synergistic, but not related to heat-promoted increased uptake of the drug. The studies were conducted at Duke University Medical Center, Durham, N.C.

  • Two inhibitors of steroid synthesis used to treat hormone-dependent breast cancer in postmenopausal women pack a significant beneficial side effect in laboratory animals. Exemestane and letrozole was shown to significantly prevent bone loss, enhance bone mechanical strength and lower serum cholesterol levels. The inhibitor drugs act by interfering with estrogen synthesis and depleting estrogen concentrations in the blood, according to the study by Goss et al., conducted at the University of Toronto, Toronto, Ontario.

    Included among the articles published in the September issue of Cancer Epidemiology, Biomarkers & Prevention:

  • High dietary cholesterol, and perhaps egg consumption, leads to increased risk for ovarian cancer, while higher intake of total vegetables and cruciferous vegetables such as broccoli, and supplementation of E, beta-carotene and B-complex vitamins was associated with reduced risk of ovarian cancer according to a study of diets reported by more than 2,500 Canadian women. The research, reported by Pan et al., was conducted by Health Canada; the OMNI Research Group, the University of Ottawa; and the Ottawa Health Research Group, Ottawa, Ontario; and the Canadian Cancer Registries Epidemiology Research Group, a consortium of Canadian.
    Current articles published in the journals of the American Association for Cancer research during the first week of September reflect an array of cutting-edge cancer research discoveries.

    For more information, or copies of the manuscripts, please contact Dr. Russell Vanderboom, AACR,, or 215-440-9300, Ext. 120.

    Founded in 1907, the American Association for Cancer Research is a professional society of more than 22,000 laboratory, translational, and clinical scientists engaged in all areas of cancer research in the United States and in more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. AACR's Annual Meetings attract more than 15,000 participants who share new and significant discoveries in the cancer field. Specialty meetings, held throughout the year, focus on the latest developments in all areas of cancer research.

    American Association for Cancer Research

    Related Ovarian Cancer Articles from Brightsurf:

    Ovarian cancer cells cooperate to metastasize
    In a study on human ovarian cancer cells in mice, Harvard Medical School researchers discovered a transient, cooperative interaction between cell subpopulations that allows otherwise nonmetastatic tumor cells to become aggressive and spread.

    Photodynamic therapy used to treat ovarian cancer
    Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.

    Studying the development of ovarian cancer with organoids
    Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions, or organoids, of the female reproductive organs of the mouse.

    New class of drugs could treat ovarian cancer
    A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

    How to catch ovarian cancer earlier
    Ovarian cancer is often diagnosed too late for effective treatment.

    New compound could help treat ovarian cancer
    Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.

    Epigenetic markers of ovarian cancer
    Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.

    Ovarian cancer statistics, 2018
    A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.

    Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
    A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

    TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
    An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.

    Read More: Ovarian Cancer News and Ovarian Cancer Current Events
  • is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to